

SPARC/Sec/SE/2019-20/035

4th October 2019

To

National Stock Exchange of India Ltd.

Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited

P J Towers,
Dalal street,
Mumbai - 400001

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: SPARC Receives **Orphan Drug** Designation from the USFDA for **Phenobarbital** for the Treatment of Patients with **Neonatal Seizures**.

Dear Sir/Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation to Phenobarbital for the treatment of patients with neonatal seizures.

The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the United States. Orphan Drug Designation will grant seven years of US market exclusivity upon approval of Phenobarbital for the treatment of patients with neonatal seizures. Incentives include waiver of user fee by USFDA and assistance in clinical trial design by USFDA.

We request you to kindly take the same on record.

Kindly take the above on record.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

A handwritten signature in black ink, appearing to read "Debashis Dey", with a horizontal line extending to the right.

Debashis Dey
Company Secretary